262 related articles for article (PubMed ID: 22190018)
1. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.
Puda A; Milosevic JD; Berg T; Klampfl T; Harutyunyan AS; Gisslinger B; Rumi E; Pietra D; Malcovati L; Elena C; Doubek M; Steurer M; Tosic N; Pavlovic S; Guglielmelli P; Pieri L; Vannucchi AM; Gisslinger H; Cazzola M; Kralovics R
Am J Hematol; 2012 Mar; 87(3):245-50. PubMed ID: 22190018
[TBL] [Abstract][Full Text] [Related]
2. Deletions of PURA, at 5q31, and PURB, at 7p13, in myelodysplastic syndrome and progression to acute myelogenous leukemia.
Lezon-Geyda K; Najfeld V; Johnson EM
Leukemia; 2001 Jun; 15(6):954-62. PubMed ID: 11417483
[TBL] [Abstract][Full Text] [Related]
3. Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies.
Kroeze LI; Nikoloski G; da Silva-Coelho P; van Hoogen P; Stevens-Linders E; Kuiper RP; Schnittger S; Haferlach T; Pahl HL; van der Reijden BA; Jansen JH
Blood; 2012 Feb; 119(5):1318-9. PubMed ID: 22308284
[No Abstract] [Full Text] [Related]
4. JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells.
Celik H; Koh WK; Kramer AC; Ostrander EL; Mallaney C; Fisher DAC; Xiang J; Wilson WC; Martens A; Kothari A; Fishberger G; Tycksen E; Karpova D; Duncavage EJ; Lee Y; Oh ST; Challen GA
Cancer Cell; 2018 Nov; 34(5):741-756.e8. PubMed ID: 30423295
[TBL] [Abstract][Full Text] [Related]
5. Deregulated Polycomb functions in myeloproliferative neoplasms.
Sashida G; Oshima M; Iwama A
Int J Hematol; 2019 Aug; 110(2):170-178. PubMed ID: 30706327
[TBL] [Abstract][Full Text] [Related]
6. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.
Jankowska AM; Szpurka H; Tiu RV; Makishima H; Afable M; Huh J; O'Keefe CL; Ganetzky R; McDevitt MA; Maciejewski JP
Blood; 2009 Jun; 113(25):6403-10. PubMed ID: 19372255
[TBL] [Abstract][Full Text] [Related]
7. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia.
Pedersen-Bjergaard J; Pedersen M; Roulston D; Philip P
Blood; 1995 Nov; 86(9):3542-52. PubMed ID: 7579462
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.
Score J; Hidalgo-Curtis C; Jones AV; Winkelmann N; Skinner A; Ward D; Zoi K; Ernst T; Stegelmann F; Döhner K; Chase A; Cross NC
Blood; 2012 Feb; 119(5):1208-13. PubMed ID: 22053108
[TBL] [Abstract][Full Text] [Related]
9. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.
Muto T; Sashida G; Oshima M; Wendt GR; Mochizuki-Kashio M; Nagata Y; Sanada M; Miyagi S; Saraya A; Kamio A; Nagae G; Nakaseko C; Yokote K; Shimoda K; Koseki H; Suzuki Y; Sugano S; Aburatani H; Ogawa S; Iwama A
J Exp Med; 2013 Nov; 210(12):2627-39. PubMed ID: 24218139
[TBL] [Abstract][Full Text] [Related]
10. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
[TBL] [Abstract][Full Text] [Related]
12. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.
Ntziachristos P; Tsirigos A; Van Vlierberghe P; Nedjic J; Trimarchi T; Flaherty MS; Ferres-Marco D; da Ros V; Tang Z; Siegle J; Asp P; Hadler M; Rigo I; De Keersmaecker K; Patel J; Huynh T; Utro F; Poglio S; Samon JB; Paietta E; Racevskis J; Rowe JM; Rabadan R; Levine RL; Brown S; Pflumio F; Dominguez M; Ferrando A; Aifantis I
Nat Med; 2012 Feb; 18(2):298-301. PubMed ID: 22237151
[TBL] [Abstract][Full Text] [Related]
13. Deletions of CDKN1B and ETV6 in acute myeloid leukemia and myelodysplastic syndromes without cytogenetic evidence of 12p abnormalities.
Andreasson P; Johansson B; Arheden K; Billström R; Mitelman F; Höglund M
Genes Chromosomes Cancer; 1997 Jun; 19(2):77-83. PubMed ID: 9171997
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
15. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
Asada S; Kitamura T
Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
[TBL] [Abstract][Full Text] [Related]
16. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.
Huh J; Tiu RV; Gondek LP; O'Keefe CL; Jasek M; Makishima H; Jankowska AM; Jiang Y; Verma A; Theil KS; McDevitt MA; Maciejewski JP
Genes Chromosomes Cancer; 2010 Apr; 49(4):390-9. PubMed ID: 20095039
[TBL] [Abstract][Full Text] [Related]
17. TEL and KIP1 define the smallest region of deletions on 12p13 in hematopoietic malignancies.
Sato Y; Suto Y; Pietenpol J; Golub TR; Gilliland DG; Davis EM; Le Beau MM; Roberts JM; Vogelstein B; Rowley JD
Blood; 1995 Aug; 86(4):1525-33. PubMed ID: 7632960
[TBL] [Abstract][Full Text] [Related]
18. [Monosomy 7: recent progress].
Inaba T; Nagamachi A
Rinsho Ketsueki; 2019; 60(9):1020-1026. PubMed ID: 31597823
[TBL] [Abstract][Full Text] [Related]
19. EZH2 in Myeloid Malignancies.
Rinke J; Chase A; Cross NCP; Hochhaus A; Ernst T
Cells; 2020 Jul; 9(7):. PubMed ID: 32650416
[TBL] [Abstract][Full Text] [Related]
20. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53.
Kanagal-Shamanna R; Bueso-Ramos CE; Barkoh B; Lu G; Wang S; Garcia-Manero G; Vadhan-Raj S; Hoehn D; Medeiros LJ; Yin CC
Cancer; 2012 Jun; 118(11):2879-88. PubMed ID: 22038701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
